This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

News
21 Aug 2013

Malvern Instruments’ CTO will Discuss New Technology for Characterizing Protein Formulations at International BioAnalytical Congress

Dr E. Neil Lewis, Chief Technology Officer at Malvern Instruments and Head of the company’s Bioscience Development Initiative, will speak at the International BioAnalytical Congress taking place in Berlin (Germany) on 11 and 12 September 2013.

 

The theme of the conference is the future of bioanalytical development and Dr Lewis will discuss ‘Advances in the integrated measurements of higher order proteins’, focusing especially on new technology that combines dynamic light scattering with Raman spectroscopy. He will examine this as a means of providing structural, thermodynamic and kinetic insights into mechanisms of protein aggregation and the factors that influence protein stability. Malvern is pleased also to be a sponsor and exhibitor at the Congress.

 

Determining the ease with which a protein therapeutic can be developed, formulated and manufactured requires non-invasive, non-destructive measurement of numerous physicochemical properties, including viscosity, protein structure and hydrodynamic size. Malvern offers a growing portfolio of analytical technologies focused on the needs of biopharmaceutical developers, including:

 

The new Viscosizer 200 which automates low volume viscosity measurement and size analysis. It is ideally placed to serve those working within biopharmaceutical preformulation and formulation development who need rapid viscosity information on a large number of low volume samples, in order to assess candidate developability.

 

Archimedes, which uses the technique of resonant mass measurement to detect and count particles in the size range 50 nm–5 µm. It is especially useful for characterising protein aggregates in formulation or buffer.

 

The Zetasizer Nano ZSP for the measurement of size, electrophoretic mobility of proteins, zeta potential of nanoparticles and surfaces, and optionally the microrheology of protein and polymer solutions. Protein mobility is one property that has been identified as a promising indicator of formulation stability, viscosity, and behavior.

 

Viscotek SEC-MALS 20 extends Malvern’s family of light scattering detectors for measuring the absolute molecular weight of proteins, macromolecules and polymers. Static light scattering is widely used within gel permeation/size exclusion chromatography (GPC/SEC) for the determination of the absolute molecular weight of protein, polymer and macromolecular species without the need for external, potentially inaccurate calibrations.

Related News

  • News Federal judge blocks Colorado's unprecedented price cap on Amgen's Enbrel

    A US federal court has halted Colorado's attempt to impose a US$31,200 annual price cap on Amgen's arthritis drug Enbrel, ruling that the pharmaceutical company would likely suffer irreparable harm. The decision represents a significant blow to...
  • News Protecting life-saving therapies: CPHI Online Podcast Series

    The latest episode of the CPHI Podcast Series dives into a critical challenge facing the pharmaceutical industry: ensuring the integrity of temperature-sensitive medications and biologics through advanced predictive technology.

  • News 2026 Outsourcing Outlook Update - pharma at a crossroads

    The pharmaceutical contract development and manufacturing organisation (CDMO) sector is experiencing unprecedented transformation, driven by evolving therapeutic complexities, geopolitical tensions, and the growing demand for specialised manufacturing ...
  • News Roche maintains German investment commitment whilst rivals scale back

    Pharmaceutical giant Roche has reaffirmed its commitment to investing in Germany, standing firm even as competitors Eli Lilly and Boehringer Ingelheim dramatically reduce their planned investments in response to controversial healthcare reforms.

  • News Women in Pharma: The History of CPHI Women in Japan

    Our monthly Women in Pharma series highlights the influential lives and work of impactful women working across the pharmaceutical industry, and how the industry can work towards making the healthcare industry and workplace more equitable and inclusive.
  • News EU drafts deal to end essential medicines shortage

    European negotiators have agreed new legislation to tackle persistent shortages of essential medicines by prioritising supply security over price in public procurement and supporting domestic pharmaceutical manufacturing with strategic funding.

  • News Thermo Fisher Scientific offloads microbiology business to PE firm Astorg

    The life sciences giant is divesting its global microbiology unit, which generated $645 million in revenue last year, to the pan-European private equity firm as part of an active portfolio management strategy. The transaction is expected to close in th...
  • News The Shift: Why Sustainability is Moving to the Centre of CPHI Milan 2026

    CPHI Online contributor David Roach takes a look at how conversations around sustainability in the pharmaceutical industry can and must be transformed into actionable deliveries, and what the inaugural CPHI Sustainability Summit means for the industry.